New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients

New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.

New treatment eliminates bladder cancer in 82% of patients

LOS ANGELES — A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.  In the majority of cases, the cancer disappeared after only three months of treatment, and almost half the patien...

Breakthrough Therapy Eradicates Bladder Cancer in 82% of Patients

In a groundbreaking development poised to revolutionize the treatment landscape for bladder cancer, researchers have unveiled TAR-200, an innovative drug-device combination designed to deliver chemotherapy directly into the bladder with unprecedented efficacy. This miniature, pretzel-shaped device encapsulates gemcitabine, a chemotherapy agent, and is introduced into the bladder via a catheter, where it steadily administers the […]

TAR-200 Achieves 82 Percent Tumor Elimination in BCG-Unresponsive NMIBC Patients

A recent study has demonstrated that TAR-200, an invest […] The post TAR-200 Achieves 82 Percent Tumor Elimination in BCG-Unresponsive NMIBC Patients first appeared on GeneOnline News. The post TAR-200 Achieves 82 Percent Tumor Elimination in BCG-Unresponsive NMIBC Patients appeared first on GeneOnline News.

TAR-200 Clears Tumors in 82% of Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

TAR-200 shows promise in treating BCG-unresponsive bladder cancer, achieving 82% tumor elimination and offering new hope for patients.